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ABSTRACT: Helminths represent a diverse category of parasitic
organisms that can thrive within a host for years, if not decades, in
the absence of treatment. As such, they must establish mechanisms
to subsist oﬀ their hosts, evade the immune system, and develop a
niche among the other cohabiting microbial communities. The
complex interplay of biologically small molecules (collectively
known as the metabolome) derived from, utilized by, or in
response to the presence of helminths within a host is an emerging
ﬁeld of study. In this Perspective, we brieﬂy summarize the current
existing literature, categorize key host−pathogen−microbiome
interfaces that could be studied in the context of the metabolome,
and provide background on mass spectrometry-based metabolomic
methodology. Overall, we hope to provide a comprehensive guide for utilizing metabolomics in the context of helminthic disease.
KEYWORDS: metabolomics, parasites, helminths, microbiome, immunology, mass spectrometry

H

elminths infect over 2 billion people worldwide;1−4 that
is, over 25% of the world’s population may have one or
more worm infections caused by parasitic roundworms
(nematodes) and/or ﬂatworms (cestodes and trematodes).
The most prevalent infections are caused by the soiltransmitted helminths (STHs), Ascaris and Trichuris, and
hookworms, which are among the roughly 20 neglected
tropical diseases designated by the WHO.5 These species alone
infect over a billion people worldwide and account for an
estimated 1.9 million disability-adjusted life years (DALYs)
due to anemia, malnutrition, and cognitive deﬁcits associated
with moderate- to high-burden infections.6
To date, there are no vaccines to treat any human helminth
infection, and there are only a few anthelmintic drugs that are
safe and eﬀective. With the lack of therapeutics and the rising
concern over the development of drug resistance, there is a
critical need to identify new therapeutic candidates. The
counterparts to applying appropriate therapy are an accurate
diagnosis and tests-of-cure. Microscopic exam and serology are
the gold standard for diagnosing helminth infections, and few
PCR-based molecular diagnostics are available;7 therefore,
identiﬁcation of new biomarkers and the testing of methodologies are key in exploring more sensitive, speciﬁc, and
dynamic diagnostics.
Historically, the biological and molecular complexities of
parasitic helminths have impeded the research on therapeutics
and diagnostics, but these have been partly overcome by the
wide use of systems biology “omics”. These approaches reveal
information on the genome, transcriptome, and proteome of
the biological agent and are revolutionizing parasitology. For
© 2021 American Chemical Society

example, the combination of genomics, transcriptomics, and
proteomics data has provided essential molecular information
about a speciﬁc tissue of interest (the nematode intestine), and
advanced bioinformatic approaches provide the means to
predict intestinal cell functional categories of seminal
importance to parasite survival.8 Such predictions can now
be experimentally tested and validated. Other examples include
interfacing helminth omics with chemogenomics that have
proven to identify and prioritize drugs and drug targets much
more successfully compared to high-throughput screening.
Moreover, such predictive models have been experimentally
validated as the identiﬁed drugs have been shown to have
broad potential (made possible due to the application of
evolutionary genomics principles),9 and a subsequent rational
drug design strategy has capitalized on parasite-speciﬁc
molecular features,10 which result in improved potency and
selectivity for the parasite versus the host.11
For helminth parasitologists, a growing ﬁeld of investigation
is metabolomics, which evaluates the downstream exogenous
and endogenous small molecules in a biological system. This
ﬁeld has shown major growth due to major advancements in
liquid chromatography combined with tandem mass spectrometry (LC-MS/MS). A multiomics approach can deepen our
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soluble egg antigen (SEA) from schistosomes for immunomodulation

S. mansoni cercariae, worms, eggs, SEA
products for immunomodulation
urine and plasma of urogenital schistosomiasis and associated bladder pathologies, Nigeria for biomarkers of pathogenesis
urine samples of urogenital schistosomiasis
and urothelial cell carcinoma, Angola for
diagnostic biomarkers
male and female adult worms from SCID
and BALB/c mice for metabolism of the
host/pathogen relationship
hamster sera, urine, bile; adult worms and
eggs for biomarkers of liver disease
excretory−secretory products (ESPs) from
ex vivo worms

Schistosoma mansoni
(blood ﬂuke)

Schistosoma mansoni
(blood ﬂuke)
Schistosoma hematobium (blood
ﬂuke)

Opisthorchis felineus
(liver ﬂuke)
Dipylidium caninum
(dog and cat tapeworm)

Schistosoma hematobium (blood
ﬂuke)
Schistosoma japonicum (blood ﬂuke)

urine samples from onchocerciasis positive
and negative individuals

somatic worm extracts and excretory−
secretory products from worm
viable and nonviable A. caninum eggs

eggs, including larval stages from stool
samples from infected individuals, Brazil
for biomarkers of infection
excretory−secretory products (ESPs) from
worms

samples

infected dog serum for host metabolites

helminth

Toxocara canis (dog
roundworm)
Ascaris lumbricoides
(human roundworm)
Nippostrongylus brasiliensis and Trichuris muris (nematodes)
Ancylostoma caninum
(dog hookworm)
Ancylostoma caninum
(dog hookworm)
Onchocerca volvulus
(ﬁlarial nematode)

49 metabolites identiﬁed from ESPs collected from worms ex vivo; 12 of which have known pharmacological properties, e.g, anti-inﬂammatory agents; top
10 polar metabolites were succinic acid (major component), lactic acid, myo-inositol, scyllo-inositol, tyrosine, malic acid, talose, glucose, glycerol, and
phenylalanine

estrogen-like metabolites in urogenital schistosomiasis cases but not in healthy humans; metabolites included catechol estrogen quinones (CEQ) and
CEQ-DNA adducts; novel metabolites derived from 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) were found in urine from urogenital
schistosomiasis cases
more diﬀerential metabolites in female worms than male worms between SCID and BALB/c mice; male worms included bile acid biosynthesis, taurine and
hypotaurine metabolism, sphingolipid metabolism, retinol metabolism, purine metabolism; enriched metabolite sets of diﬀerential metabolites in female
worms included retinol metabolism, alpha linolenic acid and linoleic acid metabolism, purine, sphingolipid, and glutamate metabolism
numerous oxysterols and related DNA adducts detected in the liver ﬂuke eggs and in bile from infected hamsters

SEAs from worms bind to Dectin-1 and Dectin-2 on dendritic cells, resulting in the synthesis of eicosanoid prostaglandin E2 and the expression of OX40
ligand, enabling them to promote the Th2 response; SEA contains analytes including docosahexaenoic acid, linoleic acid, arachidonic acid, PGE2, and
PGD2.
quantiﬁed ∼350 lipid species and characterized the lipid proﬁles of diﬀerent parasite life history stages; detected several immunomodulatory oxylipids in
the diﬀerent life cycle stages; prostaglandins highly enriched in egg preparations; resolvins were speciﬁcally detected in cercariae
in infection-only and advanced cases: low levels of host sex steroids, high levels of several benzenoids, catechols, and lipids (including ganglioside,
phosphatidylcholine, and phosphatidylethanolamine)

low molecular weight metabolites from worm products suppressed inﬂammation in a murine model of colitis and reduced cytokine secretion by human
peripheral blood mononuclear cells
prostaglandin, myristic acid, and lauric acid were found in viable but not nonviable ova isolated from dog feces; metabolites may be useful in a rapid
diagnostic screening test for the presence of viable hookworm ova
N-acetyltyramine-O,β-glucuronide (NATOG) was identiﬁed as a biomarker using LC-MS on patient urine samples; NATOG-based lateral-ﬂow
immunoassay for onchocerciasis identiﬁed 85% of the 27 patient urine samples

Gouveia et
al.27
Wangchuk et
al.28

Lui et al.26

Gouveia et
al.25

Adebayo et
al.24

Giera et al.23

Wangchuk et
al.18
Gyawali et
al.19
Globisch et
al.;20 Shirey et al.21
Kaisar et al.22

Wangchuk et
al.17

identiﬁed polar and nonpolar small molecules from worm ESPs with as many as 17 metabolites known to exhibit various pharmacological activities

reference
Zheng et
al.15
Melo et al.16

metabolic proﬁles of sera 24 h, 10 days, and 36 days postinfection showed alterations of bile acid, steroid hormone, and unsaturated fatty acid synthesis
pathways from dog host
metabolites for worm eggs: hexadecenal, 21-methyl-8Z-pentatriacontene, and 3,7,11,15-tetramethyltritriacontane; for ﬁrst-stage worm larvae: 2deoxyecdysone 22-phosphate, cholesterol ester, sphingomyelin, and cardiolipin; for third-stage worm larvae: dimethylheptatriacontane

ﬁndings

Table 1. Summary of Select Investigations Highlighting the Metabolomics of Parasitic Helminths Using Mass Spectrometry
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phenotype, the modulators are a much more complicated and
interconnected system. With the explosion of microbiome and
immunology-related research, major ﬁndings have begun to
intertwine these interactions between many organ systems and
disease states. One key facet of these interactions has been the
study of metabolic products and their origins and inﬂuence on
each system. While the gut microbiota has shown major
metabolomic inﬂuence,29 studies including the evaluation of
helminth metabolomic interactions have been lacking. Therefore, we present an outline of key areas of interaction that can
be used for hypothesis generation to evaluate the metabolome’s role during helminth infections.
Helminths and the Immune System. The immune
system has long been studied in the context of parasitic
helminths, particularly the induction of type 2 (Th2) and
regulatory T-cell (Treg) responses.30,31 Helminthic modulation of the immune system generally induces an antiinﬂammatory or immune tolerance response. These changes
have mainly been studied in the context of helminth excreted/
secreted/cell surface proteins, leaving signiﬁcant areas of
investigation to explore regarding small molecule production.
One central recurring ﬁnding that has been explored in the
context of both helminths and the microbiome is the eﬀect of
short chain fatty acids (SCFAs) on the induction of Treg
immune suppression responses.32,33
Giera et al.23 used lipidomics to characterize the lipid
proﬁles of diﬀerent life history stages of Schistosoma mansoni
and found several immunomodulatory oxylipids; speciﬁcally,
prostaglandins were highly enriched in egg preparations and
resolvins were speciﬁcally detected in cercariae. Lipidomic
analyses of soluble egg antigens (SEAs) of S. mansoni also
revealed that SEAs bind to the pattern-recognition receptors
Dectin-1 and Dectin-2 on dendritic cells, resulting in the
synthesis of eicosanoid prostaglandin E2 and the expression of
the OX40 ligand, enabling them to promote a Th2 response.22
Though these studies may not be broadly applicable to all
helminth interactions with the immune system, they
demonstrate distinct immunomodulatory components of
some helminth-derived small molecules, which suggest further
evaluation is needed at this host−pathogen interface.
Helminths and the Host Microbiome. The dysbiosis of
the gut microbiome is generally thought of in the context of
infections related to pathogenic bacteria or viruses; however,
helminths can also inhabit this community as pathogens. When
discussing this interface, one must explore the interactions
between both helminths and microbial communities as well as
the microbial communities and host health. A number of
studies in animal models and humans have shown various
chronic helminth infections can change microbiome populations and relate to disease states.34−36 For example, human
studies have shown an increased diversity of the gut
microbiome and identiﬁed conserved bacterial taxa positively
and negatively associated with soil-transmitted helminths
(STHs) in diﬀerent endemic countries, suggesting changes
associated with infection regardless of baseline variation of the
microbiomes in diﬀerent countries.37 Furthermore, the gut
microbiota responds to anthelmintic treatment; however, after
deworming, the microbiome assembles in a state that does not
resemble an uninfected state.38 These cross-kingdom interactions in the human gut ecosystem in individuals infected
with STH species have been studied at the taxonomic, genetic,
and functional levels, opening the door for undertaking key
mechanistic studies in the future. There is a need for a better

understanding of the parasites at a systems biology level, which
is essential for making progress toward applications to prevent
and treat infections by helminths.12
Metabolomics is used to proﬁle the small molecule
metabolic products of a biological specimen at a speciﬁc
condition and point in time, thereby providing a snapshot of its
physiological state. Proﬁling metabolic substrates and products
and relating them to metabolic pathways can aid in deﬁning
key “chokepoints” critical to the parasite and/or host. A
“chokepoint reaction” is deﬁned as a reaction that necessitates
a unique substrate or produces a unique product for a
biological function.3,13 If the chokepoint enzyme (of either
host or parasite origin) can be inhibited, the entire metabolic
pathway can be blocked, leading to downstream parasite
dysfunction. Pan-Nematoda conserved metabolic chokepoint
enzymes have been identiﬁed using omics driven approaches,
and a targeted repurposing approach has identiﬁed new small
molecules with broad spectrum anthelmintic activity.9,11
Taylor et al.13 used an innovative approach to generate a
compartmentalized metabolic and constraint-based model of
the parasitic nematode Brugia malayi. This model, which
divided the metabolic network into three compartments, the
cytosol and mitochondria of B. malayi and the Wolbachia
endosymbiont, predicted a set of 102 reactions essential to the
survival of the worm, including switching between aerobic and
anaerobic pathways and a novel pathway that relies on the
catabolism of glutamate to aspartate to produce energy. The
identiﬁcation of chokepoints in conjunction with a systems
biology approach can lead to a greater understanding of the
metabolic pathways essential for parasite survival, as will the
compartmentalized approach to study helminths and their
endosymbionts that enables investigators to predict essential
energy and metabolic growth pathways and identify potential
therapeutic targets to treat helminthic infections.

■

APPROACHES AND LIMITATIONS OF MASS
SPECTROMETRY-BASED METABOLOMICS
The direct study of biologically small molecules can be carried
out by nuclear magnetic resonance (NMR) or mass
spectrometry (MS). A recent publication has provided an
excellent review of NMR methodology and applications to
helminth metabolomics research.14 In this Perspective, we
highlight recent work on the metabolomics of parasitic
helminths using mass spectrometry (MS) and discuss the
possibilities of what the future might hold for parasitic
helminth metabolomics. Table 1 summarizes a select number
of studies using MS to proﬁle the metabolites of dogs infected
with Toxocara canis, the life cycle stages of the soil-transmitted
nematode (Ascaris lumbricoides), and the excretory−secretory
products from Nippostrongylus brasiliensis, Trichuris muris,
Ancylostoma caninum, schistosomes, and the dog/cat tapeworm
to study immunomodulation and the host response. Studies to
identify biomarkers in urine from individuals infected with
Onchocerca volvulus and biomarkers of liver disease caused by
Opisthorchis felineus are also included. Comprehensive reviews
on parasite metabolomics have been published by Preidis and
Hotez;12 Zheng et al.;15 Melo et al.;16 Wangchuk et al.17

■

KEY AREAS OF METABOLOMIC EXPLORATION IN
HELMINTH INFECTIONS
While it is easiest to think about the inﬂuence of the helminth
metabolome as a direct connection between pathogen and host
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Figure 1. Mass spectrometry methods used in metabolomics. (A) Targeted metabolomics analyze individual compounds deﬁned by the user.
Individual methods must be developed for each analyte. (B) A specialized form of targeted metabolomics called ﬂux analysis or ﬂuxomics is used to
identify and quantify metabolites as they move through the metabolic pathways, achieved by the introduction of heavy isotope labeled (e.g., 13C,
15
N, 2H) substrates. (C) Untargeted metabolomics generally uses a diﬀerent type of mass spectrometer to detect and measure analytes without a
priori knowledge of what is being analyzed. The heterogeneity in sensitivity and quantiﬁcation is the major limitation in comparison to targeted
methods.

Microbiomes of Helminths. The complex interactions of
microbiota with host organisms also applies to helminths
themselves. This is well-known in the ﬁlarial nematodes
(Onchocerca volvulus, Wuchereria bancrofti, and Brugia malayi)
and their endosymbiotic bacterium Wolbachia.41 This
bacterium is necessary for the reproduction and survival of
these organisms, largely due to the production of essential
nutrients for the helminths including heme, riboﬂavin, and
ﬂavin adenine dinucleotide (FAD).42
Other helminth endosymbionts (e.g., Neorickettsia) and
models of microbiome acquisitions are emerging with great
potential to discover necessary or novel metabolites as a source
of novel biology in this system.43,44 As with any endosymbiotic
relationship, challenges remain separating the symbiont from
its host but new technologies such as single cell analyses can be
applied to omic investigations with bacteria and their helminth
hosts.
Helminth/Host Metabolites as Biomarkers of Infection. As one may imagine, the diversity of parasitic helminths
and their life cycles greatly complicates the ability to study and
discuss metabolism in a cohesive manner. Classical biochemical pathways have been established for a number of
helminths, though the subject has not been revisited in recent
literature, to our knowledge.45,46 An emerging area of study in
microbial communities within animals is the production of
xenometabolites or small molecule products either synthesized
de novo or derived from host metabolites. Though this is not a
new subject, given the knowledge of the gut microbiome’s role
in bilirubin derivation/excretion and vitamin K production,

understanding of the microbiome changes following albendazole treatment since a study with samples from Kenya had
shown that albendazole treatment alters the microbiome
structure, especially in individuals infected with Necator
americanus,39 but a study in Indonesia showed that albendazole
does not aﬀect the microbiome composition.43 Of importance
is to note that changes in the microbiome are likely dependent
on the methodologies used (e.g., depth of coverage generated
by next generation sequencing platforms), burden of infection
(e.g., low vs moderate to heavy worm infections), and the
type/tropism of infection.
These population changes have been studied in the context
of direct or indirect (i.e., helminth-produced antibacterial
molecules) changes in the mechanical barriers of the GI
epithelium and immune regulation. In terms of the direct
inﬂuence of the metabolome, the microbiome has been
extensively studied in the context of small molecule regulators
with signiﬁcant ﬁndings in relation to host pathologies and are
beyond the scope of this Perspective.29 In a recent study of
human volunteers infected with Strongyloides stercoralis, the
authors report that, in addition to the observed increased alpha
diversity and decreased beta diversity of the fecal proﬁles of
infected vs noninfected individuals, there was an increased
abundance of speciﬁc metabolites in the infected individuals
(speciﬁc amino acids) and SCFAs in the noninfected
individuals.40 Suﬃce it to say, there is a wealth of emerging
evidence on the sources and eﬀects of the metabolite interplay
between host, microbes, and macrobes that could be due to
shifts in metabolite consumption/production or altered
gastrointestinal absorption.
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Untargeted metabolomics utilizes a newer generation of
quadrupole high-resolution mass spectrometers (QHRMS),
which combine front-end tandem mass spectrometry and backend high-resolution time-of-ﬂight or orbitrap technologies to
obtain mass resolutions below 1 × 10−4 daltons. This allows for
data acquisition techniques that can parse analytes using the
quadrupole mass ﬁlters and then trigger fragmentation into
product ions and collect high-resolution spectra. The ﬁngerprint of an analyte’s product ion spectra can give speciﬁc
structural information about the compound and greatly
increase conﬁdence in the metabolite identiﬁcation. While
QHRMS methods greatly increase the number of analytes that
can potentially be surveyed, the results may be skewed by the
fact that not all analytes will be equally detectable nor
quantiﬁable by one general mass spectrometry method. When
one both designs a study and compares evidence, understanding the utility and limitations of both targeted and
untargeted metabolomics approaches is essential.
Metabolomic ﬂux (also referred to as “ﬂuxomics”) can
measure and trace analytes through metabolic pathways.50,51
To do this, stable isotope (2H, 13C, 15N) labeled primary
metabolites (e.g., glucose or amino acids) are added to a model
system (e.g., parasite culture or infected animals) and
identiﬁed throughout downstream pathways due to the
measurable mass diﬀerence and quantiﬁable ratio of heavy
isotope incorporation in metabolized products. This is
particularly attractive for the study of parasitic infections
considering labeled metabolites can hypothetically be traced
between both host and parasite to elucidate essential metabolic
relationships.52
When Should Investigators Use Targeted versus
Untargeted Mass Spectrometry? In general, these experiments can be broken into hypothesis testing and hypothesis
generating. For targeted metabolomics, one would want to
evaluate the key intermediates of a metabolic pathway(s) that
are known to be dysregulated in an experimental system, such
as SCFA production from an in vivo infection model.
Fluxomics, as a subset of targeted metabolomics, is useful
when dynamic information about metabolites within a pathway
is needed. An example of this could be exploration on the
utilization of a class of metabolites or metabolic pathways (e.g.,
glycolysis/gluconeogenesis, fatty acid oxidation, purine metabolism, etc.) under various infection or treatment conditions.
Untargeted metabolomics is useful when a researcher can
modulate a system and wants to broadly explore the metabolic
changes, e.g., exploring changes in proﬁles following
anthelmintic therapy.
Harmonizing Helminth Metabolomics Methodologies. The ﬁeld of metabolomics is currently adapting to the
constant evolution of instrumentation and informatics. As
such, the harmonization of methods and materials to ensure
accurate and reproducible ﬁndings has been a moving target
for the entirety of the ﬁeld.53 Therefore, it is incumbent upon
the investigators to clearly publish detailed methods for their
metabolomics experiments and promote protocol sharing and
communication whenever possible. Below, we will detail areas
of variance in metabolomics studies to propose a framework
for key areas of methodologic harmonization going forward.
Preanalytical variables can be a major point of discordance
between metabolomics studies.54 Because metabolites do not
represent one distinct class of biological macromolecules (such
as nucleic acids or polypeptides), there can be many sources of
variability and interference. These can include the type of

advances in small molecule mass spectrometry have opened up
the ability to discover and characterize novel molecules.47
One example that may be applied to this category is the
discovery of numerous estrogen-like metabolites from
urogenital schistosomiasis cases but not in healthy humans
that were observed in urine samples and included catechol
estrogen quinones (CEQ) and CEQ-DNA adducts. Novel
metabolites derived from 8-oxo-7,8-dihydro-2′-deoxyguanosine
(8-oxodG) were also identiﬁed in urine from all 40 urogenital
schistosomiasis cases.24 Similar experiments in broader surveys
of helminth infections will be of great importance for
characterizing biologically relevant compounds and biomarkers
of pathogenesis.
An interesting example of a biomarker that is both a parasiteand host-derived metabolite is N-acetyltyramine-O,β-glucuronide (NATOG).20 NATOG is a neurotransmitter derived
from a combination of metabolic steps occurring in both the
nematode and host; tyramine, a neurotransmitter from
Onchocerca volvulus, is acetylated by the worm to form Nacetylturamine, which is glucuronidated by the host. This
biomarker is being used to develop a lateral-ﬂow immunoassay
for the diagnosis of onchocerciasis or river blindness,21 a
chronic disease that aﬀects roughly 18 million people in mostly
low/middle income countries in sub-Saharan Africa.
Other potential biomarkers were identiﬁed in serum and
urine samples from humanized mice infected with O. volvulus
using LC-MS/MS.48 The study focused on worm-derived
proteins and found that, of all the proteins that were identiﬁed,
155 were detected from infected mice and not the from the
control mice. This study also noted that the proteins that were
most likely to be useful as biomarkers were among those with
an unknown function, and due to the low number and
abundance of O. volvulus-speciﬁc proteins, samples had to be
pooled from each group of mice for analysis. The study points
to the challenges helminthologists face when attempting to
identify many of the novel parasite metabolites. It is essential
that newly generated helminth-related metabolomic data
(including metabolite structures and their reference spectra)
are submitted in public databases (e.g., MetaboLights49) along
with information on the metabolomics experiment and derived
information, so that novel metabolites that have not been
previously reported can be documented and, in the future, be
conﬁrmed in independent experiments in the same or diﬀerent
helminth species.

■

OVERVIEW OF MASS SPECTROMETRY-BASED
METABOLOMICS
With a number of interesting metabolomic interfaces to
explore, understanding the methodology is key to designing
and controlling for meaningful results. Below, we have
provided a comprehensive overview of small molecule mass
spectrometry techniques and how they may be applied to the
study of parasitic helminths.
Targeted versus Untargeted Mass Spectrometry.
Mass spectrometry techniques for metabolomics can be
broadly separated into three categories: targeted, untargeted,
and ﬂux studies (Figure 1).
Targeted mass spectrometry utilizes triple quadrupole mass
analyzers, which isolate each analyte of interest for the
detection and quantiﬁcation with an individually optimized
method. Compound-related stable isotope internal standards
are used to normalize for preanalytical and analytical variation
of the assay, greatly improving accuracy and precision.
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library, where all standards were run on the same instrument
parameters as the specimens, will provide the highest
conﬁdence in accurate metabolite identiﬁcation.
The statistical approach of data analysis becomes a second
source of postanalytical variance; however, this is not speciﬁc
to metabolomic studies and therefore beyond the scope of this
article. It will suﬃce to say that the most common forms of
metabolomic data analysis include volcano plots, hierarchical
clustering, and multivariate component analyses, of which the
speciﬁcs of the data set and experimental questions are key for
choosing the appropriate statistical approach. While many of
these approaches can be performed using general statistical
software, resources such as MetaboAnalyst provide robust data
analysis tools appropriate for metabolomics data with curated
tutorials and guidance.59

specimen collection devices, metabolite extraction protocols,
and lipid depletion strategies to name a few. Overall, how the
sample is handled and prepared may lead to a diﬀerential
representation of individual metabolites or metabolite classes
entering the mass spectrometer for analysis.
Understanding natural variabilities of specimen types is also
important for appropriate metabolomics study design. For
example, the metabolomic variability of stool specimens is
expected to be much higher than that of peripheral blood
considering the gut contents will include all variations in diet,
where the serum reﬂects only a physiologically balanced net
absorption/excretion of gut products. Delineations must even
be accounted for between seemingly equivalent specimens,
such as serum and plasma, considering the higher content of
protein from clotting factors can aﬀect extraction eﬃciency.
Analytically, one must take into consideration both the
chromatography and modality of mass spectrometry when
analyzing study design. Both gas chromatography (GC) and
liquid chromatography (LC) are established for the upfront
separation of analytes and as a parameter of data analysis.
Advances in ultra high-performance liquid chromatography
(UHPLC) and column chemistry have brought LC-MS to the
forefront of metabolomic methods. However, GC is still
predominantly used for the analysis of volatiles (alcohols,
esters, ketones, etc.) and SCFAs. Even within LC, it is not
uncommon that two UHPLC methods, such as reverse phase
and hydrophilic interaction (HILIC), will be run on each
sample to achieve appropriate separation for polar, semipolar,
and nonpolar metabolites. Even then, the exact choice of
column chemistry can aﬀect conﬁdence in compound
detection.55
When confronting the variability of the mass spectrometry
component, the most important factor in study design is the
source of library spectra for metabolite identiﬁcation. Diﬀerences in mass spectrometry source and compound-dependent
parameters of a method can create diﬀerent product ion
spectra, which can confound identiﬁcation and quantiﬁcation.
Ideally, one’s metabolomics experiments should be analyzed
with the same method parameters in the same mass
spectrometry facility when at all possible.
Postanalytical Variables. Postanalytical variables in
metabolomics mostly relate to data analysis, which encompasses conﬁdence in metabolite identiﬁcation (for untargeted
data) and statistical analysis approaches for large metabolite
data sets. Each metabolite identiﬁcation by LC-MS has three
major components: (1) LC retention time (RT), (2) mass
accuracy to the theoretical chemical formula, and (3) product
ion spectra library match. Metabolomics standards initiatives
(MSIs) have sought to grade conﬁdence in metabolite
identiﬁcation by assigning conﬁdence levels utilizing these
components.56,57 The decision to align with MSI conﬁdence
level criteria or to deﬁne a diﬀerent system is largely up to the
researcher but should be clearly outlined within the methodology of a subsequent publication. The ability to get to high
conﬁdence identiﬁcations relies greatly on the quality and
source of product ion spectral libraries, which are produced by
curating method-speciﬁc product ion spectra of authentic
standards or in silico prediction. Online spectral libraries58
provide an attractive resource for searching the largest number
of metabolites possible; however, the quality of the spectral
data can vary greatly depending on the analyte standard used
to generate the library entry and the MS method parameters
(as noted above). When possible, using an in-house spectral

■

HARMONIZATION OF METABOLOMIC
METHODOLOGY AND FUTURE DIRECTIONS FOR
STUDYING PARASITIC HELMINTHS

Given the diversity of parasitic helminths, it is essential for the
ﬁeld to harmonize metabolomic experimentation to increase
conﬁdence in the reproducibility of the ﬁndings and in
undertaking comparative metabolomic studies. One key
bottom-up approach would be the utilization of helminthspeciﬁc protocols for sample collection, preparation, and
metabolite extraction. Metabolomics data repositories, such
as Metabolomics Workbench60 (https://www.
metabolomicsworkbench.org), provide the capacity for standardized formatting and open access for these protocols. As the
ﬁeld evolves, a more centralized parasitic helminth database for
combining metabolomic, proteomic, and transcriptomic/
genomic data would be an ideal source for the community.
Another direction for increasing harmonization would be
specialized metabolomics centers for parasitic diseases.
Metabolomics-driven science is often broadly generalized to
any type of sample sets, yet aspects of study design and
biological interpretation may be key to understanding the
unique and divergent biology of helminths under the dynamic
conditions of host−parasite interactions. The development of a
center combining primary metabolomics methodologists and
infectious diseases experts will be essential for producing high
quality studies that innovate the ﬁeld.

■

CONCLUSIONS

Metabolomics can be studied in the context of helminth
infections in a number of ways including in vitro parasite
culture, in vivo animal models, or clinical studies in humans.
The results and conclusions derived from this research must
encompass the interconnected systems of helminth infections,
human immunology, and microbiome dysbiosis (of both the
worm and host). Major areas of focus for studying
metabolomics in helminth infections include understanding
and characterizing helminth-derived small molecule and
metabolic interactions in the context of pathogenesis, drug
design, and biomarker discovery. Lastly, for this research to
provide meaningful and reproducible metabolomic ﬁndings,
researchers must take it upon themselves to be versed in the
strengths and limitations of the methodology and advocate
best practices of this mass spectrometry-driven science.
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